(VIANEWS) – Pinduoduo (PDD), United Therapeutics Corporation (UTHR), Columbus McKinnon Corporation (CMCO) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Pinduoduo (PDD)
114.3% sales growth and 34.92% return on equity
PDD Holdings Inc., a multinational commerce group, owns and operates a portfolio of businesses. It operates Pinduoduo, an e-commerce platform that offers products in various categories, including agricultural produce, apparel, shoes, bags, mother and childcare products, food and beverage, electronic appliances, furniture and household goods, cosmetics and other personal care, sports and fitness items and auto accessories; and Temu, an online marketplace. It focuses on bringing businesses and people into the digital economy. The company was formerly known as Pinduoduo Inc. and changed its name to PDD Holdings Inc. in February 2023. PDD Holdings Inc. was incorporated in 2015 and is based in Dublin, Ireland.
Earnings Per Share
As for profitability, Pinduoduo has a trailing twelve months EPS of $3.87.
PE Ratio
Pinduoduo has a trailing twelve months price to earnings ratio of 38.44. Meaning, the purchaser of the share is investing $38.44 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 34.92%.
Volume
Today’s last reported volume for Pinduoduo is 3991140 which is 50.11% below its average volume of 8000580.
Yearly Top and Bottom Value
Pinduoduo’s stock is valued at $148.75 at 04:22 EST, higher than its 52-week high of $147.65.
Moving Average
Pinduoduo’s worth is way higher than its 50-day moving average of $109.18 and way above its 200-day moving average of $86.11.
2. United Therapeutics Corporation (UTHR)
18.7% sales growth and 17.52% return on equity
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhance the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing OreniPro, RemoPro, Tyvaso DPI, Trevyent, Ralinepag, and Aurora-GT to treat PAH; Unexisome to treat bronchopulmonary dysplasia; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. It has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin; Caremark, L.L.C. to provide refills of implanted pumps at its infusion centers; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder and Dreamboat devices; and Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Earnings Per Share
As for profitability, United Therapeutics Corporation has a trailing twelve months EPS of $18.12.
PE Ratio
United Therapeutics Corporation has a trailing twelve months price to earnings ratio of 13.51. Meaning, the purchaser of the share is investing $13.51 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.52%.
Yearly Top and Bottom Value
United Therapeutics Corporation’s stock is valued at $244.86 at 04:22 EST, way under its 52-week high of $281.40 and way higher than its 52-week low of $204.44.
Moving Average
United Therapeutics Corporation’s value is above its 50-day moving average of $229.46 and higher than its 200-day moving average of $227.15.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 58.8% and 14.6%, respectively.
Revenue Growth
Year-on-year quarterly revenue growth grew by 18.1%, now sitting on 2.2B for the twelve trailing months.
3. Columbus McKinnon Corporation (CMCO)
5.8% sales growth and 6.23% return on equity
Columbus McKinnon Corporation designs, manufactures, and markets intelligent motion solutions to ergonomically move, lift, position, and secure materials worldwide. The company offers electric, air-powered, lever, and hand hoists; hoist trolleys, explosion-protected and custom engineered hoists, and winches; crane systems, such as crane components and kits, enclosed track rail systems, mobile and jib cranes, and fall protection systems, as well as material handling solutions; rigging equipment comprising below-the-hook lifting devices, shackles, chains and chains accessories, forestry and hand tools, lifting slings, lashing systems, and tie-downs and load binders; rotary unions and swivel joints; and mechanical and electromechanical actuators. It also provides power and motion technology products, including AC motor controls and line regenerative systems, automation and diagnostics, brakes, cable and festoon systems, collision avoidance systems, conductor bar systems, DC motor and magnet control systems, elevator drives, inverter duty motors, mining drives, pendant pushbutton stations, radio controls, and wind inverters; power delivery subsystems; overhead aluminum light rail workstations; and low profile, flexible chain, large scale, sanitary, and vertical elevation conveyor systems, as well as pallet system conveyors and accumulation systems. The company serves market verticals, including general industries, transportation, energy and utilities, process industries, industrial automation, construction and infrastructure, food and beverage, entertainment, life sciences, consumer packaged goods, and e-commerce/supply chain/warehousing. It offers its products to end users directly, as well as through distributors, independent crane builders, material handling specialists and integrators, government agencies, original equipment manufacturers, and engineering procurement and construction firms. The company was founded in 1875 and is headquartered in Buffalo, New York.
Earnings Per Share
As for profitability, Columbus McKinnon Corporation has a trailing twelve months EPS of $1.77.
PE Ratio
Columbus McKinnon Corporation has a trailing twelve months price to earnings ratio of 20.34. Meaning, the purchaser of the share is investing $20.34 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.23%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Columbus McKinnon Corporation’s EBITDA is 1.53.
Revenue Growth
Year-on-year quarterly revenue growth grew by 11.5%, now sitting on 978.11M for the twelve trailing months.
Sales Growth
Columbus McKinnon Corporation’s sales growth for the next quarter is 5.8%.
4. OFG Bancorp (OFG)
5.5% sales growth and 17.39% return on equity
OFG Bancorp, a financial holding company, provides a range of banking and financial services. It operates through three segments: Banking, Wealth Management, and Treasury. The company offers checking and savings accounts, as well as time deposit products; commercial, consumer, auto leasing, and mortgage lending services; financial planning and insurance services; and corporate and individual trust, and retirement services. In addition, it provides securities brokerage and investment advisory services, including various investment alternatives, such as tax-advantaged fixed income securities, mutual funds, stocks, and bonds to retail and institutional clients; and separately-managed accounts and mutual fund asset allocation programs. Further, the company engages in the insurance agency and reinsurance businesses; administration and servicing of retirement plans; various treasury-related functions with an investment portfolio consisting of mortgage-backed securities, obligations of U.S. government sponsored agencies, and U.S. Treasury securities and money market instruments; and management and participation in public offerings and private placements of debt and equity securities. Additionally, it offers money management and investment banking services; and engages in the asset/liability management activities, such as purchases and sales of investment securities, interest rate risk management, derivatives, and borrowings. OFG Bancorp was founded in 1964 and is headquartered in San Juan, Puerto Rico.
Earnings Per Share
As for profitability, OFG Bancorp has a trailing twelve months EPS of $3.81.
PE Ratio
OFG Bancorp has a trailing twelve months price to earnings ratio of 9.14. Meaning, the purchaser of the share is investing $9.14 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.39%.
